Drug intelligence / Profile preview

SHR-A1811 + oxaliplatin + levo-leucovorin + fluorouracil + bevacizumab

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This investigational combination regimen is being evaluated as a first-line treatment for advanced colorectal cancer. It consists of **SHR-A1811**, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC), combined with the **mFOLFOX6** chemotherapy backbone (comprising oxaliplatin, levo-leucovorin, and fluorouracil) and **bevacizumab**, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody. SHR-A1811 is composed of a trastuzumab-derived antibody conjugated to a topoisomerase I inhibitor payload via a cleavable linker. The regimen is designed to leverage the targeted cytotoxicity of the ADC alongside standard-of-care chemotherapy and anti-angiogenic therapy to improve outcomes in patients with HER2-expressing advanced colorectal cancer.

Other names: SHR-A1811 + oxaliplatin + levo-leucovorin + fluorouracil + bevacizumab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on SHR-A1811 + oxaliplatin + levo-leucovorin + fluorouracil + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-A1811 + oxaliplatin + levo-leucovorin + fluorouracil + bevacizumab.

Explore the full profile